Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2501 to 2550 of 3761 results for treatment

  1. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.

  2. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

  3. Endoscopic stapling of pharyngeal pouch (HTG8)

    Evidence-based recommendations on endoscopic stapling of pharyngeal pouch. This involves stapling the opening of the pharyngeal pouch through a specially designed endoscope.

  4. AccuVein AV400 for vein visualisation (MIB6)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation

  5. About evidence summaries

    Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.

  6. Balloon catheter insertion for Bartholin's cyst or abscess (HTG204)

    Evidence-based recommendations on balloon catheter insertion for Bartholin's cyst or abscess. This involves making a passage from the cyst or abscess through which the gland can drain by inflating a small, specially designed balloon.

  7. Minimally invasive oesophagectomy (HTG272)

    Evidence-based recommendations on minimally invasive oesophagectomy. This involves making small cuts or holes in the chest wall and inserting a camera and other instruments into the chest cavity to carry out the operation.

  8. Looked-after children and young people (QS31)

    This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.

  9. Electrotherapy for the treatment of haemorrhoids (IPG525)

    We have moved interventional procedures guidance 525 to become HealthTech guidance 377. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. Surgical site infections: prevention and treatment (CG74)

    This guidance has been updated and replaced by NICE guideline NG125.

  11. NICE and virtual wards

    We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.

  12. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

  13. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

  14. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  15. Lung cancer: diagnosis and treatment (CG24)

    This guideline has been updated and replaced by NICE guideline CG121.

  16. Prostate cancer: diagnosis and treatment (CG58)

    This guidance has been updated and replaced by NICE guideline CG175.

  17. Assessing motility of the gastrointestinal tract using a wireless capsule (HTG351)

    Evidence-based recommendations on assessing motility of the gastrointestinal tract using a wireless capsule. This involves swallowing a capsule that sends bowel information as it passes through the digestive system.

  18. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (HTG460)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.

  19. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

  20. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

  21. Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula (HTG359)

    Evidence-based recommendations on insertion of a collagen plug to close an abdominal wall enterocutaneous fistula. This involves inserting a collagen plug into the fistula to seal off where it joins the bowel.

  22. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

  23. Auditory brain stem implants (HTG65)

    Evidence-based recommendations on auditory brain stem implants for deafness caused by damage to the vestibulocochlear nerve due to tumours or surgery. This involves placing an implant in the part of the brain that processes sound signals, bypassing the nerve, to pick up electrical signals from a sound processor worn outside the ear.

  24. Vagus nerve stimulation for refractory epilepsy in children (HTG25)

    Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.

  25. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)

    Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.

  26. Holmium laser prostatectomy (HTG5)

    Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.

  27. News, blogs and podcasts

    for people with breathing condition, COPD, as NICE approves innovative treatment Breakthrough therapy reduces flare-ups by almost a...

  28. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

  29. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

  30. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)

    Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.

  31. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  32. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).

  33. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

  34. Stockholm3 for prostate cancer screening (MIB303)

    NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .

  35. Macimorelin for diagnosing growth hormone deficiency (MIB320)

    NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .

  36. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  37. Endoscopic saphenous vein harvest for coronary artery bypass grafting (HTG342)

    Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).

  38. Intraoperative nerve monitoring during thyroid surgery (HTG164)

    Evidence-based recommendations on intraoperative nerve monitoring during thyroid surgery. This involves placing electrodes near the vocal cords to alert the surgeon when a surgical instrument comes close to either of the laryngeal nerves.

  39. Image-guided radiofrequency excision biopsy of breast lesions (HTG198)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

  40. Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD) (HTG189)

    Evidence-based recommendations on combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD). This involves accessing the bones of the hip and pelvis through a cut made on the thigh and correcting the deformity as much as possible.

  41. Therapeutic percutaneous image-guided aspiration of spinal cysts (HTG143)

    Evidence-based recommendations on therapeutic percutaneous image-guided aspiration of spinal cord cysts. This involves using a needle to drain the cyst and remove pressure on the spinal cord or nerve roots.

  42. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

  43. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (HTG450)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  44. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  45. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

  46. Key question: safe

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.